Rna Diagnostics Selected to Participate in EXCITE Program to Evaluate RDA
6/21/2013 9:36:54 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TORONTO, Ontario -- Rna Diagnostics, Inc. (RnaDx) has been accepted into the MaRS Excellence in Clinical Innovation and Technology Evaluation (EXCITE) program for the clinical evaluation of their diagnostic test, RNA Disruption Assay™ (RDA™),and its impact on patient care for individuals undergoing breast cancer chemotherapy. Through EXCITE, The Toronto Health Economics and Technology Assessment (THETA) initiative will be evaluating RDA™ in a provincial multi-centre clinical trial to assess both patient health outcomes and health care savings related to the use of RDA™.
The goal of MaRS EXCITE is to enable better health technologies to get to market faster, leading to improved health outcomes. Rna Diagnostics is one of three businesses selected to participate in this pilot program.
The participation of the three health care technologies in the pilot round was announced today by the Honourable Deb Matthews, Minister of Health and Long-Term Care, Ontario at MEDEC’s 2013 MEdTech conference in Toronto.
“The RDA™ technology has the potential to change the standard of care for women with breast cancer. Patients could be saved from enduring the side effects of an ineffective treatment, and quickly changed to an alternate treatment, which can also save the health system tremendous costs in unnecessarily delivering expensive medication in instances where it clearly is not working. Through EXCITE, the RDA™ technology will undergo rigorous testing to generate the right evidence to prepare it for reimbursement review and market adoption. If the results are as anticipated, the EXCITE process will get the RDA™ technology to patients faster for improved health outcomes,” said Dr. Leslie Levin, CSO, MaRS EXCITE.
President and CEO of Rna Diagnostics, Dr. Ken Pritzker said, “As RDA™ holds the prospect of dramatically improving patient care for breast cancer in the near future, Rna Diagnostics is delighted to be participating in the MaRS EXCITE pilot project. Success with MaRS EXCITE is likely to accelerate the advance of RDA™ towards world-wide adoption.”
About Rna Diagnostics Inc.
Rna Diagnostics is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RNA Disruption Assay™ (RDA™), determines early in a woman’s breast cancer treatment whether she is responding to the chemotherapy. If the chemotherapy is not working effectively she can be switched quickly to other treatment, avoiding the harmful side-effects of ineffective chemotherapy and thereby improving her outcome. For more information on Rna Diagnostics, please visit www.rnadiagnostics.com
Help employers find you! Check out all the jobs and post your resume.